Low-Field-Strength Body MRI: Challenges and Opportunities at 0.55 T.

Advances in MRI technology have led to the development of low-field-strength (hereafter, "low-field") (0.55 T) MRI systems with lower weight, fewer shielding requirements, and lower cost than those of traditional (1.5-3 T) systems. The trade-offs of lower signal-to-noise ratio (SNR) at 0.55 T are partially offset by patient safety and potential comfort advantages (eg, lower specific absorption rate and a more cost-effective larger bore diameter) and physical advantages (eg, decreased T2* decay, shorter T1 relaxation times). Image reconstruction advances leveraging developing technologies (such as deep learning-based denoising) can be paired with traditional techniques (such as increasing the number of signal averages) to improve SNR. The overall image quality produced by low-field MRI systems, although perhaps somewhat inferior to 1.5-3 T MRI systems in terms of SNR, is nevertheless diagnostic for a broad variety of body imaging applications. Effective low-field body MRI requires (a) an understanding of the trade-offs resulting from lower field strengths, (b) an approach to modifying routine sequences to overcome SNR challenges, and (c) a workflow for carefully selecting appropriate patients. The authors describe the rationale, opportunities, and challenges of low-field body MRI; discuss important considerations for low-field imaging with common body MRI sequences; and delineate a variety of use cases for low-field body MRI. The authors also include lessons learned from their preliminary experience with a new low-field MRI system at a tertiary care center. Finally, they explore the future of low-field MRI, summarizing current limitations and potential future developments that may enhance the clinical adoption of this technology. ©RSNA, 2023 Supplemental material is available for this article. Quiz questions for this article are available through the Online Learning Center. See the invited commentary by Venkatesh in this issue.

AAPM Task Group Report 325: MRI static magnetic field homogeneity measurement and evaluation procedures - Guidance and resources.

Measurement of static magnetic field (B0) homogeneity is an essential component of routine MRI system evaluation. This report summarizes the work of AAPM Task Group (TG) 325 on vendor-specific methods of B0 homogeneity measurement and evaluation. TG 325 was charged with producing a set of detailed, step-by-step instructions to implement B0 homogeneity measurement methods discussed in the American College of Radiology (ACR) MRI Quality Control Manual using specific makes and models of MRI scanners. The TG produced such instructions for as many approaches as was relevant and practical on six currently available vendor platforms including details of software/tools, settings, phantoms, and other experimental details needed for a reproducible protocol. Because edits to these instructions may need to be made as vendors enter and exit the market and change available tools, interfaces, and access levels over time, the step-by-step instructions are published as a living document on the AAPM website. This summary document provides an introduction to B0 homogeneity testing in MRI and several of the common methods for its measurement and evaluation. A living document on the AAPM website provides vendor-specific step-by-step instructions for performing these tests to facilitate accurate and reproducible B0 homogeneity evaluation on a routine basis.

Alzheimer's Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for ARIA Monitoring.

With the full FDA approval and centers for Medicare & Medicaid services (CMS) coverage of lecanemab and donanemab, a growing number of practices are offering anti-amyloid immunotherapy to appropriate patients with cognitive impairment (MCI) or mild dementia due to amyloid-positive Alzheimer's disease (AD). The goal of this paper is to provide updated practical considerations for radiologists, including implementation of MR imaging protocols, workflows and reporting and communication practices relevant to anti-amyloid immunotherapy and monitoring for amyloid-related imaging abnormalities (ARIA). Based on consensus discussion within an expanded ASNR Alzheimer's, ARIA, and Dementia study group, we will: (1) summarize the FDA guidelines for evaluation of radiographic ARIA; (2) review the three key MRI sequences for ARIA monitoring and standardized imaging protocols based on ASNR-industry collaborations; (3) provide imaging recommendations for three key patient scenarios; (4) highlight the role of the radiologist in the care team for this population; (5) discuss implementation of MRI protocols to detect ARIA in diverse practice settings; and (6) present results of the 2023 ASNR international neuroradiologist practice survey on dementia and ARIA imaging.ABBREVIATIONS: AD = Alzheimer's disease; ARIA = amyloid-related imaging abnormalities; APOE = apolipoprotein-E; CMS = centers for Medicare & Medicaid services; MCI = mild cognitive impairment.

Diffusion of myelin water.

We studied compartmentally specific characteristics of water diffusion in excised frog sciatic nerve by combining T1 or T2 selective acquisitions with pulse-gradient spin-echo (PGSE) diffusion weighting, with the specific objective of characterizing myelin water diffusion. Combining a PGSE with a Carr-Purcell-Meiboom-Gill (CPMG) acquisition provided apparent diffusion coefficients (ADCs) for each of the three T2 components found in nerve, including the short-lived component believed to be derived from myelin water. Double-inversion-recovery (DIR) preparation provided an alternate means of discriminating myelin water, and in combination with PGSE provided somewhat different measures of ADC. The DIR measures yielded myelin water ADCs of 0.37 microm2/ms (parallel to nerve) and 0.13 microm2/ms (perpendicular to nerve). These ADC estimates were postulated to be more accurate than those based on T2 discrimination, although the difference between the two findings is not clear.